Stockscreener 앱 받기
1.91
3.24%
0.06
전일 마감가:
$1.85
열려 있는:
$1.85
하루 거래량:
73,276
Relative Volume:
0.03
시가총액:
$25.48M
수익:
$2.14M
순이익/손실:
$-15.44M
주가수익비율:
-0.6172
EPS:
-3.0946
순현금흐름:
$-24.67M
1주 성능:
+4.95%
1개월 성능:
-5.91%
6개월 성능:
-52.49%
1년 성능:
-93.73%
1일 변동 폭
$1.81
$1.92
1주일 범위
$1.745
$1.92
52주 변동 폭
$1.50
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
명칭
Tvardi Therapeutics Inc
전화
(713) 489-8654
주소
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
1.91 | 24.41M | 2.14M | -15.44M | -24.67M | -3.0946 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-10-14 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-10-14 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-10-13 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | 개시 | Raymond James | Outperform |
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 개시 | Piper Sandler | Overweight |
| 2025-05-21 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 개시 | BTIG Research | Buy |
| 2024-06-13 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | 다운그레이드 | Needham | Buy → Hold |
| 2024-06-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-03-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-11-01 | 재개 | Canaccord Genuity | Buy |
| 2021-08-03 | 개시 | JP Morgan | Neutral |
| 2020-04-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-29 | 재확인 | Laidlaw | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2019-01-15 | 개시 | BofA/Merrill | Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Jefferies | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-12 | 재개 | H.C. Wainwright | Buy |
| 2018-02-12 | 업그레이드 | Janney | Neutral → Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
모두보기
Tvardi Therapeutics Inc 주식(TVRD)의 최신 뉴스
Tvardi stock falls as investors book gains after Phase 1 data - scanx.trade
symbol__ Stock Quote Price and Forecast - CNN
BTIG Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative ColitisSlideshow - Seeking Alpha
Tvardi Therapeutics: TTI-109, an oral STAT3 inhibitor, targets unmet needs in UC with promising safety and efficacy data - TradingView
Tvardi Therapeutics: TTI-109 targets STAT3 to address unmet needs in UC with selective immune modulation and safety - TradingView
Tvardi Therapeutics: TTI-109 offers targeted STAT3 inhibition with improved safety and efficacy for UC and HCC - TradingView
H.C. Wainwright reiterates Tvardi stock rating citing UC pivot - Investing.com
H.C. Wainwright reiterates Tvardi stock rating citing UC pivot By Investing.com - Investing.com UK
Tvardi Reports $6.5 Million Second-Quarter Net Loss and TTI-109 UC Plans - Moomoo
Tvardi Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Tvardi Q2 net loss reaches $6.5 million - grafa.com
H.C. Wainwright Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Tvardi Therapeutics Reports Q2 2026 Net Loss of $6.5 Million - Minichart
Tvardi Therapeutics | 8-K: Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update - Moomoo
Tvardi Q2 EPS $(0.69) beats $(0.70) estimate, loss narrows 31% - scanx.trade
Form 8K Tvardi Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Tvardi Therapeutics, Inc. 2026: Revenue ($6.46M), EPS ($0.69) — 10-Q Summary - TradingView
Tvardi Reports Positive TTI-109 Data, Picks Ulcerative Colitis for Next-Gen Drug - Minichart
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update - The Manila Times
Tvardi Therapeutics: Q2 2026 saw a $6.5M net loss, cash of $15.8M, and urgent need for additional funding - TradingView
Tvardi posts Q2 2026 net loss of $6.5M, cash $15.8M; reports TTI-109 healthy volunteer topline - TradingView
Tvardi Therapeutics Reports Topline Healthy Volunteer Results for TTI-109 and Selects Ulcerative Colitis as Initial Indication - Quiver Quantitative
Tvardi Therapeutics: TTI-109 advanced for UC after positive topline results; Q2 net loss was $6.5 million - TradingView
Tvardi: Q2 Earnings Snapshot - 10TV
BRIEF-Tvardi Therapeutics Inc Q2 Net Income USD -6.5 Million Vs. IBES Estimate USD -6.54 Million - TradingView
Tvardi Therapeutics (TVRD) Holds Ground at $1.77 Amid Cautious Biotech SentimentBullish Pattern Stocks - Vinanet
Tvardi Therapeutics to Host KOL Webinar on the Clinical - GlobeNewswire
JonesTrading Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Tvardi Therapeutics, Inc. Revenue Breakdown – NASDAQ:TVRD - TradingView
Tvardi Therapeutics, Inc. expected to post a loss of 70 cents a shareEarnings Preview - TradingView
Enterprise value to revenue forward of Tvardi Therapeutics Inc. – FWB:69C - TradingView
Raymond James upgrades Tvardi Therapeutics stock rating on Phase 1 data - Investing.com Nigeria
TVRD Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Tvardi Therapeutics Ord Shs (TVRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109, Plans 2027 Clinical Trial - Quiver Quantitative
Tvardi Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Pipeline ProgressEarnings Manipulation Risk - dars.gov.et
TVRD|Tvardi Therapeutics Ord Shs|Price:2.555|Chg%:+0.045 - TradingKey
Tvardi Therapeutics Ord Shs (TVRD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tvardi Therapeutics Ord Shs (TVRD) Institutional Confidence - TradingKey
Tvardi Therapeutics (TVRD) Edges Higher, Testing Key Resistance LevelsCall Flow Alert - vinanet.vn
Tvardi Therapeutics Inc. Revenue Breakdown – LS:A414VY - TradingView
TVRD Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Pre-Revenue Phase - vinanet.vn
Tvardi Therapeutics Inc. Revenue Breakdown – LSX:A414VY - TradingView
Tvardi Therapeutics, Inc. (NASDAQ: TVRD) Share Price, TVRD Stock News, TVRD Share Price & Updates - Kalkine
Tvardi Therapeutics (TVRD) Holds Near Support After Modest DeclineDip Buy Trade - vinanet.vn
Tvardi Therapeutics Company Profile & Introduction - Moomoo
ONDS: Ondas Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Tvardi Therapeutics Expands At-The-Market Equity Program - The Globe and Mail
Form 424B5 Tvardi Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Tvardi Therapeutics | 8-K: Current report - Moomoo
Tvardi Therapeutics Inc (TVRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):